Abbott Laboratories

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Data from AbbVie and Johnson & Johnson will fine-tune OpenFold3 in a confidentiality-preserving environment, powered by Apheris.

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross domestic product. McKinsey & Co. follows suit, noting AI could generate 30% efficiency gains and cost savings in the pharmaceutical sector and trigger financial gains of up to $110 billion annually.

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company") has been honored with the "Most Valuable Investment Award" at the 10th China Medical Industry Innovation Competition,

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

Johnson & Johnson signed a multibillion-dollar contract with ChemImage in 2019. The two companies will face off in court next week.

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases offering training for it.

ABBYY's CEO, Ulf Persson, highlights the significance of its first-ever AI Research & Development (R&D) center in Bengaluru, emphasizing the company's commitment to innovation in an era of rapid AI advancements and India's role in it.